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Flexible synthesis of cationic peptide–porphyrin
derivatives for light-triggered drug delivery and
photodynamic therapy†
R. Dondi,‡a E. Yaghini,‡b K. M. Tewari,a L. Wang,a,c F. Giuntini,§a M. Loizidou,b
A. J. MacRobertb and I. M. Eggleston*a
Eﬃcient syntheses of cell-penetrating peptide–porphyrin conjugates are described using a variety of bio-
conjugation chemistries. This provides a ﬂexible means to convert essentially hydrophobic tetrapyrolle
photosensitisers into amphiphilic derivatives which are well-suited for use in light-triggered drug delivery
by photochemical internalisation (PCI) and targeted photodynamic therapy (PDT).
Introduction
Photodynamic therapy (PDT) is a light-based therapeutic tech-
nique that shows great promise for the selective treatment of a
variety of cancers and non-malignant conditions.1 The prin-
ciple of PDT is that highly localised destruction of tumours,
diseased tissue or pathogenic organisms is achieved with light
following the administration of a light-activated photosensitis-
ing drug or photosensitiser. This generates various cytotoxic
reactive oxygen species such as singlet oxygen that can interact
with and damage cellular components, leading to cell death.
Many photosensitisers have been developed and have received
approval or clinical trials for use in the treatment of cancer,2
age-related macular degeneration,3 pre-cancerous conditions
such as Barret’s oesphagus,4 and oral sterilisation in dental
procedures.5 Among these, porphyrins and other tetrapyrrole-
related compounds remain the broadest class of compound
under study for PDT and other light-based therapies.6 The
eﬀectiveness of PDT in a particular application depends upon
the wavelength at which the photosensitiser may be activated,
and this has led to the development of many modified tetra-
pyrroles that show enhanced absorption at the red end of the
spectrum where absorption by tissue is relatively weak, thus
allowing a photodynamic eﬀect at a greater depth in vivo.6,7
Another important consideration in the development of novel
photosensitisers is their eﬃcient delivery to the target site, in
particular achieving selective delivery of photosensitisers to
tumours compared to normal tissues. In this context, in recent
years there has been considerable interest in the development
of peptide and protein-targeted photosensitisers as a means of
improving the pharmacokinetic properties, solubility and
tissue specificity of various otherwise hydrophobic derivatives.
Conjugation of photosensitisers to antibodies and a range of
synthetic peptides has been explored and has been found to
provide significant enhancements in both the eﬃciency and
selectivity of cellular uptake of photosensitisers for PDT in a
range of cancer models.8 A key innovation in the development
of such targeted photosensitisers has been the application of
biorthogonal ligation techniques9 which facilitate the eﬃcient
attachment of a variety of photosensitisers to unprotected,
multifunctional peptides in solution.
Cell-penetrating peptides (CPPs) are an intensely researched
class of biocompatible carriers which have great potential for
targeted drug delivery.10–12 Such molecules, of either natural
or synthetic origin typically consist of 8–30 amino acid resi-
dues and possess the ability to translocate across biological
membranes and transport diverse molecular cargoes, either co-
valently or non-covalently attached, which would otherwise be
poorly internalised. The conjugation of tetrapyrrole-based
photosensitisers and other derivatives to CPPs has indeed
been shown to provide an attractive means for enhancing
photosensitiser delivery for both PDT of cancer13–15 and in
antimicrobial PDT applications.16,17 Importantly, CPP-conju-
gation also oﬀers a means to control the sub-cellular localis-
ation of a particular photosensitiser in eukaryotic systems to
potentially maximise therapeutic eﬀect.10,14
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We recently demonstrated that the conjugation of a por-
phyrin derivative to a cationic CPP is an eﬀective way of gener-
ating a novel water-soluble amphiphilic photosensitiser suit-
able for light-triggered drug delivery by photochemical intern-
alisation (PCI).18 PCI is a novel technology for eﬀecting the
light-activated intracellular release of biologically active mole-
cules at specific sites in living tissue, often where conventional
methods of drug administration prove unsuccessful.19,20 The
eﬀectiveness of various macromolecular therapeutic agents
can often be severely impaired by their limited ability to reach
their intracellular targets due to sequestration in endosomes
and lysosomes after uptake by endocytic mechanisms. PCI pro-
vides a highly eﬀective means to selectively trigger endosomal
escape and intracellular relocalisation of entrapped drugs, by
applying the basic principle of the PDT approach. In PCI,
a sub-lethal light dose is applied to a photosensitiser that
localises in endo/lysosomal membranes, which is suﬃcient
to cause partial rupture of these intracellular organelles
(mediated by singlet oxygen). This allows the entrapped drugs
to escape but does not compromise the viability of the cells
themselves.20 Recent clinical studies have demonstrated both
the feasibility and safety of PCI for the treatment of advanced
and recurrent solid malignancies.21
A critical requirement in PCI is that the photosensitiser
used must possess features that make it localise in the same
intracellular vesicles (lysosomes, endosomes) as the adminis-
tered drug, i.e. they must be lysosomotropic and therefore
amphiphilic.20 Many well-known PDT photosensitisers are
unsuitable for PCI as they partition non-selectively to other cel-
lular organelles (e.g. mitochondria, Golgi apparatus, endoplas-
mic reticulum), however as shown in Fig. 1, attachment of an
otherwise hydrophobic photosensitiser derivative to a cationic
CPP may transform it into an amphiphilic compound that is
both water-soluble and amenable to cellular uptake by endo-
cytosis.18 The hydrophobic porphyrin macrocycle then has the
potential to localise in the lipid bilayer of the endosomal mem-
branes, for selective oxidative damage,22,23 with the hydro-
philic peptide in the fluid phase.18 These properties are ideally
suited for PCI (see above).
The application of CPP-targeted photosensitisers for PCI
and PDT depends on the availability of reliable synthetic proto-
cols to derivatise typical cationic CPPs in a site-specific
fashion24 with easily accessible functionalised photosensiti-
sers of maximum clinical potential.25 The aim of this study
was to investigate the potential of a number of bioconjugation
reactions for the eﬃcient modular preparation of CPP–
porphyrin conjugates, as a general strategy to convert classical
PDT agents into amphiphilic conjugates suitable for targeted
PDT and PCI.
Results and discussion
Photosensitiser synthesis
The preparation of the ligatable photosensitisers used in this
study is outlined in Scheme 1. As in previous studies by us,
meso-tetrakistetraphenylporphyrin 1 provided the template for
these compounds, and was transformed to the mono-amino
derivative 2 by a modification of the method of Luguya et al.26
Treatment of 1 with sodium nitrite and trifluoroacetic acid
under the reported conditions (3 min contact time) gave a
mixture of mono- and dinitrated porphyrins that were reduced
directly with sodium borohydride and palladium on charcoal.
2 was then easily separated from disubstituted products and
unchanged 1 in reproducible yields of around 30% over the
two steps. The porphyrin scaﬀold was then elaborated with
several functionalities that would permit biorthogonal ligation
with a suitably modified CPP component, via acylation with a
suitable carboxylic acid component using either EDC/HOBt or
PyBOP activation.27 Compounds 3–8 were obtained in satisfac-
tory yields via either activation protocol, and in the cases of 3
and 8 were used directly with their complementary ligatable
CPP partners (see below). The azido and alkynyl derivatives
5–7 were further converted into the corresponding zinc com-
plexes by treatment with Zn(OAc)2 in DCM in excellent yields,
ready for use in copper-catalysed ligation reactions.
Peptide synthesis
All peptides were synthesised by 9-fluorenylmethoxycarbonyl
(Fmoc) peptide synthesis on Rink amide resin, using PyBOP
activation. Peptides 10–14 were based on the decapeptide CPP
sequence derived from the transcriptional activator (Tat)
protein from human immunodeficiency virus 1 (HIV-1),
commonly known as HIV-1 Tat(48–57),28 which provided the
template for N-terminally ligatable derivatives in this study. In
each case, the final peptide was functionalised on-resin to
introduce a complementary reactive group to permit one of the
following ligation chemistries with the appropriate porphyrin
derivative. Peptides 10–12 were obtained via straightforward
acylation of the resin-bound peptide with either Fmoc-L-Cys-
OH (for 10), azidoundecanoic acid (for 11), or pentynoic acid
(for 12), using HATU activation.27 For peptide 13, an
N-terminal azido function was introduced by direct diazo
transfer upon the resin-bound Tat sequence using the Stick
reagent (imidazole-1-sulfonyl azide hydrochloride),29 with
Fig. 1 Amphiphilic CPP-targeted photosensitiser. The hydrophobic
photosensitiser unit localises in the lipid bilayer of endosomal/lysosomal
vesicles while the cationic peptide carrier resides in the ﬂuid phase.
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completion of the reaction being assessed by the Kaiser test,30
as for the on-resin acylations to generate 10–12. In the case of
the keto-functionalised derivative 14, acylation of the resin-
bound peptide could only be satisfactorily achieved using the
preformed succinimido ester of pyruvic acid.31 Other activation
methods (DIC, PyBOP, HATU) failed to give desired product,
presumably due to the tendency of keto acids such as pyruvate
to undergo Claisen-type condensations under strong carboxyl
activation conditions.32 The C-terminally ligatable peptides
15–18 were obtained directly by standard solid phase peptide
synthesis. Cys-containing peptide 15, was originally reported
by Santra et al.33 and is also based upon the HIV-1 Tat(48–57)
sequence. It provided the template for our prototype CPP-
targeted photosensitiser for PCI and applications in anti-
microbial PDT.17,19 Azidopeptide 16 was derived from 15, by
replacement of the terminal Cys residue with ε-azidolysine34
and insertion of a Gly residue at the C-terminus itself, to facili-
tate loading of the Rink amide resin. Azidopeptides 17 and 18
were obtained in an analogous fashion by respectively the
replacement of one Lys residue in the sequence of pVEC, a
CPP derived from murine vascular endothelial-cadherin
protein, or a fragment of penetratin, a CPP derived from the
Antennapedia homeoprotein.12 The final N-terminally functio-
nalised CPPs 11–14 were obtained in yields of 35–58%, and
the C-terminally functionalised derivatives 15–18 in yields of
59–67% after cleavage from the resin and side chain de-
protection with TFA/TIS/H2O or TFA/TIS/H2O/EDT, for Cys-con-
taining peptides 10 and 15 (Scheme 2).
Scheme 1 Synthesis of ligatable porphyrin derivatives.
Scheme 2 Preparation of N- and C-terminally ligatable CPP derivatives.
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Ligation reactions
Thiol-maleimide and oxime ligation. There are many
examples of the ligation of porphyrin-type photosensitisers to
multifunctional peptides and proteins with a suitably placed
Cys residue via conjugate addition to a maleoyl-type or other
α,β-unsaturated carbonyl function.9,35 Recently, Bryden et al.36
have used dibromopyridazinediones as the electrophilic unit
as part of a ligation strategy to couple cationic porphyrins to
a targeting antibody. In order to compare the eﬃciency of
N- and C-terminal ligation with the cationic Tat sequence,
peptides 10 and 15 were reacted with a two-fold excess of
porphyrin 31 17,37 in DMSO as shown in Scheme 3. This furnished
the desired CPP conjugates 19 and 20 in excellent yields, with
Scheme 3 Bioconjugations of functionalised porphyrins to CPP derivatives. The azidolysine-derived residue in conjugates 27–29 is highlighted in
bold. Conjugates 27 and 28 contain a spacer residue (Gly) between the azidolysine and the C-terminus.
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no significant diﬀerence in the eﬃciency of N-terminal or
C-terminal attachment. This is in contrast to a report by
Kitagishi et al.37 who observed that an analogous ligation to
the N-terminus of an octaarginine derivative proceeded only in
very low yield. Indeed, using an alternative polar ligation at the
N-terminus of the Tat-CPP unit via keto peptide 14 also proved
to be highly eﬀective. In this case, the Boc-protected porphyrin
4 was first treated with TFA in DCM to generate aminoxyderiva-
tive 9, which isolated as the free base in 94% yield. The comp-
lementary fully deprotected peptide 14 was then treated with a
four-fold excess of 9 in 0.1% TFA/DMSO to give the desired
oxime conjugate in 75% yield following purification by semi-
preparative HPLC. DMSO proved to be the solvent of choice for
these ligations as a compromise between the otherwise
mutually exclusive solubilities of the highly hydrophobic
porphyrins and the unprotected peptides, since preliminary
studies with water/PEG systems were found to give very slug-
gish reactions and variable yields. Notwithstanding this, it was
typically possible to greatly simplify the isolation of 19–21 and
similar conjugates by precipitation of the crude products or
removal of the reaction solvent by isolation on a solid-phase
extraction cartridge prior to semi-preparative HPLC.
Copper-catalysed azide–alkyne cycloaddition (CuAAC).
Various examples of the ligation of photosensitisers to peptide
derivatives using copper-catalysed azide–alkyne cycloaddition
(CuAAC) have been described,38 however the potential of this
approach appears to have been very little exploited with poly-
cationic CPPs as the targeting agent.39,40 Although maleimide
and oxime ligations proved quite satisfactory for our appli-
cations, ligation by copper-catalysed CuAAC oﬀered a number
of advantages. As well as generating a triazole-containing
linkage that is completely stable under physiological con-
ditions, an additional attractive feature was the possibility to
easily introduce one or other of the azide and alkyne functions
into either photosensitiser or CPP components, at the N- or
C-termini, and with a range of spacer units As a direct com-
parison for the chemistry of N-terminal attachment, the
alkynyl and azido porphyrins 5 and 6 were first combined with
the corresponding functionalised Tat peptides 11 and 12
respectively to generate isomeric conjugates 22 and 24 that
diﬀer only in the location of the triazole moiety within the
linker (Scheme 3). Preliminary tests aimed at devising the
optimum reaction conditions confirmed the need for the Zn(II)
complexes of both 5 and 6 to avoid sequestration of the copper
catalyst by the macrocycle.41 When peptides 11 and 12 were
thus reacted with an excess of complexes Zn-5 and Zn-6 in the
presence of CuSO4 and sodium ascorbate in DMSO/H2O/
tBuOH, the N-linked corresponding conjugates were success-
fully obtained in reproducible yields of 45% and 77% respect-
ively. Conjugates 22 and 24 were isolated by preparative HPLC,
and the zinc was easily and quantitatively removed from the
porphyrin unit by diluting the reaction mixture with aqueous
TFA prior to purification. When the porphyrin component was
replaced with azido derivative Zn-7, applying the same reaction
conditions with Tat peptide 11 also gave the desired conjugate
25 in very good yield (78%); shortening the spacer between the
porphyrin unit and the azido function thus appeared to have
no serious adverse eﬀect on the cycloaddition reaction. No
improvement in yields was observed when the copper source
was replaced with a Cu(I) reagent in these reactions (e.g.
Cu(OTf)),42 although the conjugations also proceeded, though
generally less eﬃciently, in the absence of tert-butanol as co-
solvent. Reaction of alkynyl-porphyrin 5 and peptide 13, in the
presence of CuSO4 and ascorbic acid in DMSO in fact gave the
desired conjugate again in very high yield (78%). Thus, even
incorporating the azido function directly at the N-terminus of
the polyfunctional CPP sequence (mutating Gly to azidoacetyl)
appeared to be well tolerated for this ligation.
Strain-promoted azide–alkyne cycloaddition (SPAAC). While
it was found to be possible to eﬃciently ligate simple azido or
alkynyl porphyrins to the N-terminus of a complementary Tat
peptide in either sense via CuAAC chemistry, a general draw-
back of this approach is the need to protect the porphyrin
macrocycle via pre-formation of a Zn complex. Furthermore,
preliminary studies with other porphyrin and chlorin deriva-
tives suggested that significant reaction optimisation might be
required on a case-by-case basis depending on the precise
photosensitiser structure.43
Recent advances in biorthogonal ligation chemistry44–46
have yielded a range of novel variants on the original triazole
approach in which the use of a strained alkyne component
removes the need for copper catalysis, and this has indeed
recently been shown to be suitable for generating specific por-
phyrin–antibody conjugates.36 We chose to investigate SPAAC
ligations for the eﬀective synthesis of both N- and C-terminally
linked CPP–porphyrin conjugates, and as described above, por-
phyrin derivative 8 bearing a strained dibenzocyclooctyne
(DBCO) function could be readily prepared by acylation of 2
with the commercially available carboxylic acid derivative.
Owing to the chemical reactivity of the DBCO unit, the pre-
ferred sense of combination was with the azido function in the
peptide component as detailed above, either through
N-terminal acylation with a suitable azidoalkanoic acid (Tat
peptide 12), or by incorporation of a C-terminally located azi-
dolysine (peptides 16–18). Reaction of 2 eq. of DBCO por-
phyrin 8 with the N-terminal azido Tat peptide 12 proceeded
smoothly in DMSO to give the expected conjugate 26 in 65%
yield as an inseparable mixture of triazole regioisomers.44
Again there was no significant loss of eﬃciency upon switch-
ing from an N- to C-terminal ligation: combination of 8 with
the relevant C-terminally ligatable Tat peptide 16 also pro-
ceeded eﬀectively to give conjugate 27 in 50% yield after HPLC
isolation. When 8 was combined with the penetratin and
pVEC derivatives 17 and 18, once again the desired
C-terminally ligated conjugates 28 and 29 were obtained with
high eﬃciency irrespective of the length of the peptide com-
ponent and without requiring a significant excess of 8 (see
Scheme 3).
Uptake and subcellular localisation of CPP conjugates
The eﬃcient uptake and endolysosomal localisation of the
amphiphilic CPP-photosensitiser conjugates was determined
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by microscopy in MC28 rat fibrosarcoma cells. All the N- and
C-terminally linked conjugates studied showed the expected
sub-cellular localisation predicted for their overall amphiphilic
character (see Fig. 1) and which would render them potentially
suitable photosensitisers for PCI applications. Fig. 2 shows
typical images demonstrating the eﬃcient uptake of C-linked
derivative 20. This parallels the behaviour of 20 previously
observed in the clinically important HN5 head and neck
cancer cell line, wherein greatly enhanced cellular uptake of
the porphyrin moiety is provided by the function of the CPP to
which it is conjugated.18 Endolysosomal localisation of the
conjugate was confirmed by colocalisation of the porphyrin
fluorescence with Lysotracker Green as visualised by the yellow
colour in the merged image in Fig. 2C. All the conjugates were
highly water soluble, unlike the parent porphyrin 1 and func-
tionalised but non-ligated porphyrins 2–8.
Phototoxicity
The localisation of CPP-targeted porphyrin derivatives in lyso-
somal compartments should result in a highly eﬃcient tar-
geted PDT eﬀect, if as desired, the photosensitiser is localised
in the membrane of these vesicles where singlet oxygen
generated can eﬀectively photo-oxidise unsaturated lipid
materials.20 The photoxicities of selected N- and C-linked con-
jugates were therefore examined in monolayer culture in MC28
and MCF-7 human breast cancer cells. A significant photo-
induced reduction in cell viability was observed with both N-
and C-terminally linked maleoyl conjugates 19 and 20 in
MC28 cells, which was enhanced with increased photosensiti-
ser concentration and dose of blue light. Comparison of 19
and 20 however revealed little diﬀerence in performance as a
result of switching the photosensitiser location within the
peptide carrier (Fig. 3).
Importantly, Fig. 3 shows that control experiments in the
dark for both conjugates resulted in no chemical toxicity at
concentrations that were significantly greater than those typi-
cally employed for in vitro PCI experiments (see below). This
confirmed that the observed reduction in cell viability was
light-induced rather than being associated with any mem-
brane-disrupting eﬀects due to the CPP moiety. The triazole
conjugates 24 and 26 also displayed a concentration and light
dose-dependent increase in the PDT eﬀect (Fig. 4), again
Fig. 2 Cellular uptake and colocalisation of conjugate 20 with LysoTracker Green in MC28 cells using laser scanning confocal microscopy. Cells
were incubated with 20 (2.5 µM) for 24 h. LysoTracker Green (100 nM) was applied to cells 30 min before imaging. A: 20 alone, B: LysoTracker
Green, C: merged A and B inset ﬁgure highlighting the overlap of ﬂuorescence from 20 and LysoTracker Green. Scale bar: 20 µm.
Fig. 3 PDT eﬀect of 19 (A) and 20 (B) in MC28 cells. Cells were incubated with Tat–porphyrin conjugates at various concentrations and were illumi-
nated with a blue lamp for up to 5 min. MTT assay was carried out 48 h after light exposure. Data are presented as mean value ± standard deviation
(SD) of three independent experiments.
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without dark toxicity under the experimental conditions.
Table 1 shows the porphyrin dose required to induce 50% tox-
icity (LD50) after 5 min illumination for the four conjugates 19,
20, 24, and 26. These values show that while the PDT perform-
ance is indeed similar for 19 and 20 (N- vs. C-terminal por-
phyrin conjugation), connecting the hydrophobic porphyrin
and the polycationic hydrophilic peptide components via the
more extended triazole-based linker of 26 seems to be highly
beneficial. Notwithstanding this observation, the spectroscopic
properties of the porphyrin unit did not appear to be aﬀected
by peptide ligation for these or any of the conjugates
(see ESI†).
Finally, the C-terminally linked triazole conjugate 29 exem-
plifying SPAAC ligation was evaluated in MCF7 cells. Once
again, an eﬀective concentration and light dose-dependent
reduction in cell viability was observed (Fig. 5), with LD50 =
449 nM for 7 min irradiation. As expected, no dark toxicity was
shown when the cells were incubated with 29 at various con-
centrations up to 1 µM.
Light-triggered drug delivery
Two of the N-terminally linked Tat conjugates, 19 and 26 were
studied further for their ability to promote light-induced re-
localisation and endosomal escape of a co-administered protein
toxin. Saporin is a 30 kDa ribosome inactivating protein,
which has been widely used in neuronal research and as a
model compound for PCI studies. Upon cellular uptake, it is
ordinarily entrapped within lysosomes, thus severely limiting
its toxicity. PDT treatment and PCI of saporin with 19 and 26
resulted in almost the same level of cytotoxic response for
each compound (Fig. 6). This data shows that for the PCI
experiments the eﬀect of combining either conjugate with
saporin is synergistic rather than additive. Indeed, with both
conjugates a significant reduction in cell viability was observed
in PCI-treated cells versus PDT-treated cells (p < 0.0001). For
example at 5 min illumination in Fig. 6B for 26, PCI resulted
in a four-fold reduction in viability compared to PDT. PCI
eﬃcacy is defined as the ratio of the viability measured using
PDT over the PCI viability, and since the reduction in
viability using saporin alone is small (approximately 10% in
either case) this ratio gives a measure of the enhancement in
saporin cytotoxicity induced by PCI.47 In the absence of
eﬀective light-triggered endolysosomal disruption and saporin
release, the PDT : PCI ratio would be near unity. The ratios
observed here of 3.3 for 19 and 4.0 for 26 showing that
eﬀective PCI is induced and to similar extents in both conju-
gates, notwithstanding the diﬀerence in the CPP-photo-
sensitiser linkage.
Fig. 4 PDT eﬀect of 24 (A) and 26 (B) in MC28 cells. Cells were incubated with Tat–porphyrin conjugates at various concentrations and were
illuminated with a blue lamp for up to 5 min. MTT assay was carried out 48 h after light exposure. Data are presented as mean value ± SD of three
independent experiments.
Table 1 LD50 values for PDT for Tat-porphyrin conjugates in MC28
cells following 5 min illumination. Estimated errors are SDs
Compound LD50 PDT (nM) LD50 dark (µM)
19 114 ± 8 ≫1
20 94 ± 6 ≫1
24 108 ± 6 ≫1
26 37 ± 2 ≫1
Fig. 5 PDT eﬀect of 29 in MCF-7 cells. Cells were incubated with
photosensitiser at various concentrations and were illuminated with a
blue lamp for up to 7 min. The MTT assay was carried out 48 h after light
exposure. Data are presented as mean value ± SD of three independent
experiments.
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Experimental
General information
Chemical reagents were purchased from Sigma-Aldrich, Fluka,
Acros, Novabiochem, and Bachem. Peptide grade DMF was
purchased from Rathburn Chemicals. Anhydrous DCM was
obtained by distillation over calcium hydride. Dowex-1 basic
anion exchange resin 100–200 mesh (hydroxide form) was pur-
chased from Sigma and was activated by overnight soaking in
2 M aq. NaOH; the beads were then washed with deionised
water and with MeOH. All other solvents were purchased from
Fisher Scientific and used as received. Analytical TLC was
performed using silica gel 60 F254 pre-coated on aluminium
sheets (Merck). Column chromatography was performed on
silica gel 60 (35–70 micron) from Sigma-Aldrich. Melting
points were recorded on an Electrothermal IA9200 melting
point apparatus in open capillaries, and are quoted un-
corrected. UV spectra were recorded on a Perkin-Elmer
Lambda 19 uv/vis spectrophotometer. Fluorescence spectra
were recorded on a Cary Eclipse fluorimeter. 1H and 13C NMR
were recorded using a Varian Mercury-VX spectrometer at
400 MHz (1H) and 100 MHz (13C) or a Bruker Avance III 500 at
500 MHz (1H) and 125 MHz (13C). Chemical shift values are
given in ppm (δ). J values are given in Hz. Analytical RP-HPLC
was performed on a Dionex Ultimate 3000 system (Dionex,
UK), with a VWD-3400 variable wavelength detector, and a
RF-2000 fluorescence detector. Analyses were performed at
35 ± 0.1 °C on a Gemini 5 μ C18 110A column, (150 × 4.6 mm –
Phenomenex, UK), equipped with a Security Guard C18 (ODS)
4 × 3.0 mm ID guard column (Phenomenex, UK), at a flow rate
of 1 mL min−1. Mobile phase A was 0.1% aq. TFA, mobile
phase B was 0.1% TFA in MeCN. (Method 1: 0.0–10.0 min
0–95% B, 10.0–15.0 min 95% B, 15.0–15.1 min at 95–5% B,
15.1–18.0 min 5% B. Method 2: 0.0–10.0 min 0–95% B,
10.0–20.0 min 95% B, 20.0–20.1 min at 95–5% B,
20.1–23.0 min 5% B). Preparative RP-HPLC was performed on
a Dionex HPLC system equipped with a Phenomenex Gemini
5 μ C18 (250 × 10 mm) column at a flow rate of 2.5 mL min−1.
Solid phase extractions were performed with Supelco Discovery
DSC-18 cartridges (2 g). High resolution mass spectrometry
was performed using a Bruker MicroTOF autospec ESI mass
spectrometer.
5-(4-Aminophenyl)-10,15,20-triphenylporphyrin (2)
The method of Luguya et al.26 was modified as follows.
Nitration: a solution of meso-tetrakistetraphenylporphyrin 1
(1.60 g, 2.60 mmol) in TFA (80 mL) in an air-open round-
bottom flask was treated at 18 °C with NaNO2 (321 mg,
4.64 mmol). After 3 min, the reaction was quenched with H2O
(40 mL), then transferred to a separatory funnel and further
diluted with H2O (80 mL) and DCM (160 mL). After separation,
the aqueous phase was extracted with DCM (2 × 150 mL). The
organic phases were combined, washed with saturated aq.
NaHCO3 (2 × 175 mL) and brine (175 mL), then dried over
MgSO4. The combined organic phases were filtered and evapo-
rated to give a residue (1.89 g), which was used directly in the
next step. Reduction: a solution of the preceding crude mixture
of unreacted 1 and mono- and dinitrated products in DCM
(640 mL) and MeOH (160 mL) in an air-open round-bottom
flask was treated with 5% Pd/C (320 mg). NaBH4 (241 mg,
63.7 mmol) was added in small portions with stirring during
10 min, then the mixture was stirred for an additional 15 min.
The reaction was quenched by the addition of H2O (150 mL),
and the resulting suspension was transferred to a separatory
funnel. The organic phase was separated, washed with brine
(100 mL), dried over MgSO4, filtered and evaporated. The
crude product was purified by column chromatography,
eluting first with toluene to remove unreacted 1 (589 mg, 37%
recovery), then 0–10% EtOAc in DCM to elute 2 (564 mg, 34%
from 1) and then diaminoporphyrins (368 mg, 22% from 1).
The spectroscopic data (1H NMR, 13C NMR) were indistinguish-
able from the literature.26
Preparation of ligatable porphyrins (3)–(8)
Compounds 3 and 5–7 were prepared according to the general
procedure detailed below.
General procedure: a stirred solution of amino derivative 2
(0.08 mmol) in anhydrous DCM (2.5 mL) was treated with the
Fig. 6 Light-induced cytotoxic response for 19 (A) and 26 (B) in MC28
cells, showing PDT (without saporin) and PCI (with saporin) eﬀects. Cells
were incubated with photosensitiser (50 nM) with or without saporin
(20 nM) for 18 h. Irradiation was carried out for 3 and 5 min with a blue
lamp. MTT assay was carried 72 h after irradiation. The experiments were
repeated 3 times, and representative data are shown. Error bars = SD.
Statistically signiﬁcant diﬀerence between PCIconjugate 19-saporin versus
PDTconjugate 19 (p < 0.0001) is indicated by ***. Likewise, statistically
signiﬁcant diﬀerence between PCIconjugate 26-saporin versus PDTconjugate 26
(p < 0.0001) is indicated by ***.
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corresponding carboxylic acid (0.16 mmol), followed by EDC
(0.16 mmol), HOBt (0.16 mmol) and DIPEA (0.47 mmol). The
solution was protected from light and stirred under nitrogen
at room temperature overnight. The reaction mixture was
diluted with DCM, washed with 0.1 M HCl, saturated aq.
NaHCO3, and brine. The organic phase was dried (MgSO4),
filtered, and the solvent was evaporated. The crude product
was purified by column chromatography (0–20% EtOAc/DCM
gradient).
5-[4-(3-Maleimido)-propionylamidophenyl]-10,15,20-triphenyl-
porphyrin (3).17,37 Scale: 0.08 mmol. Dark purple solid (43 mg,
69%). mp 278–280 °C; UV-Vis (CHCl3), nm (%): 418 (100), 515
(6.8), 550 (5.1), 590, (4.1), 646 (3.7); 1H NMR (400 MHz,
(CD3)2SO) δ 8.88 (m, 8H), 8.28–8.19 (m, 10H), 7.90 (m, 9H),
7.14 (s, 2H), 3.90 (t, J = 9.6, 2H), 2.77 (t, J = 9.6, 2H), −2.85
(s, 2H); 13C NMR (100 MHz, (CD3)2SO) δ 170.9, 169.0, 141.2,
135.9, 134.7, 134.2, 129.0, 128.6, 128.1, 127.0, 120.0, 119.9,
117.7, 42.1, 35.9, 34.0; HRMS [found (ESI+) 781.2927 [M + H]+,
C51H37N6O3 requires 781.2916].
5-{4-[2-(Bis-tert-butoxycarbonylaminooxy)-acetyl]-amidophenyl}-
10,15,20-triphenylporphyrin (4). A solution of the amino
derivative 2 (0.10 mmol) in DCM (2 mL) was treated with
2-(bis-tert-butoxycarbonylaminooxy)acetic acid (0.30 mmol),
followed by PyBOP (0.30 mmol) and DIPEA (0.60 mmol). The
solution was protected from light and stirred under nitrogen
at room temperature, until TLC showed consumption of 2. The
reaction mixture was diluted with DCM, washed with 10% aq.
citric acid, saturated aq. NaHCO3, and brine. The organic
phase was dried (MgSO4), filtered, and the solvent was evapor-
ated. The crude product was purified by column chromato-
graphy (EtOAc/40–60 petrol gradient) and recrystallised from
DCM/MeOH to give 4 as a dark purple solid (60 mg, 67%); mp
289–291 °C; UV-vis (CHCl3), nm (%): 418 (100), 515 (6.7), 549
(4.5), 590 (4.5), 590 (3.8), 646 (3.6); 1H NMR (400 MHz, CDCl3)
δ 10.25 (s, 1H), 8.87–8.81 (m, 8H), 8.20–8.17 (m, 8H), 8.05 (d,
J = 6.4, 2H), 7.76–7.68 (m, 9H), 4.71 (s, 2H), 1.61 (s, 18H),
−2.76 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 167.0, 166.3, 150.9,
142.2, 135.1, 134.5, 127.7, 126.7, 120.1, 119.6, 118.0, 85.7, 28.1;
HRMS [found (ESI+) 903.3817 [M + H]+, C56H51N6O6 requires
903.3870].
5-[4-(4-Pentynoyl)-amidophenyl]-10,15,20-triphenylporphyrin
(5). Scale: 0.11 mmol. Dark purple solid (42 mg, 52%); mp
277–279 °C; UV-Vis (CHCl3), nm (%): 418 (100), 515 (9.1), 550
(7.0), 589 (6.2), 645 (5.8); 1H NMR (500 MHz, (CD3)2SO) δ 10.45
(s, 1H), 8.89 (m, 8H), 8.24–8.07 (m, 10H), 7.89–7.83 (m, 9H),
2.92 (s, 1H), 2.74 (m, 2H), 2.62 (m, 2H), −2.91 (s, 2H);
13C NMR (100 MHz, (CD3)2SO) δ 170.9, 169.5, 142.1, 138.3,
137.4, 135.5, 128.5, 128.3, 127.7, 126.7, 120.2, 118.1, 70.0, 69.5,
62.8, 36.5; HRMS [found (ESI+) 710.2907 [M + H]+, C49H36N5O
requires 710.2920].
5-[4-(11-Azido)-undecanoylamidophenyl]-10,15,20-triphenyl-
porphyrin (6). Scale: 0.11 mmol. Dark purple solid (37 mg,
40%); mp 221-224 °C; UV-vis (CHCl3), nm (%): 419 (100),
515 (5.6), 549 (5.0), 589 (3.2), 646 (2.9); 1H NMR (400 MHz,
(CD3)2SO) δ 10.36 (s, 1H), 8.97–8.82 (m, 8H), 8.27–8.11 (m,
10H), 7.92–7.83 (m, 9H), 3.32 (t, J = 6.8, 2H), 2.50 (t, J = 7.2,
2H), 1.77 (m, 2H), 1.54 (m, 2H), 1.42–1.22 (m, 12H), −2.82
(s, 2H); 13C NMR (100 MHz, (CD3)2SO) δ 171.7, 141.2, 139.4,
135.6, 134.7, 134.2, 131.2, 128.0, 127.0, 120.1, 119.9, 119.8,
117.4, 50.6, 36.6, 28.9, 28.8, 28.8, 28.7, 28.5, 28.2, 26.1; HRMS
[found (ESI+) 839.4185 [M + H]+, C55H51N8O requires
839.4186].
5-[4-(11-Azido)-butanoylamidophenyl]-10,15,20-triphenyl-
porphyrin (7). Scale: 0.08 mmol. Dark purple solid (37 mg,
62%); mp 200–201 °C dec.; UV-Vis (CHCl3), nm (%): 419, 549,
589; 1H NMR (400 MHz, CDCl3) δ 8.88–8.80 (m, 8H), 8.22–8.19
(m, 6H), 8.13 (d, J = 8.0, 2H), 7.81–7.72 (m, 9H), 7.41 (s, 1H),
3.50 (t, J = 6.5, 2H), 2.52 (t, J = 6.5, 2H), 2.11 (m, 2H), −2.75
(br, 2H); 13C NMR (100 MHz, CDCl3) δ 170.2, 142.0, 138.1,
137.3, 135.1, 134.5, 127.7, 126.7, 120.2, 119.4, 117.9, 60.4, 50.7,
34.1, 24.6, 21.1, 14.2; HRMS [found (ESI+) 731.3074 [M + H]+,
C48H37N8O requires 731.3085].
5-[4-(6-Dibenzoazacyclooctynecaproateamido)ethylamido
phenyl]-10,15,20-triphenylporphyrin (8). A solution of 2
(20.0 mg, 0.031 mmol) in anhydrous DCM (5 mL) was treated
with HOBt (5.0 mg, 0.036 mmol), dibenzocyclooctyne-acid
(10.0 mg, 0.030 mmol), EDC (7.0 mg, 0.036 mmol) and DIPEA
(15.6 μL, 0.09 mmol) and was stirred at room temperature over-
night. The solvent was evaporated and the crude product was
purified directly by column chromatography, eluting with 10%
acetone/DCM. This gave 8 as a red solid (21 mg, 70%); mp
>250 °C; UV-Vis (CHCl3), nm: 420, 516, 553, 594, 694;
1H NMR
(500 MHz, (CD3)2SO, 60 °C) δ 10.03 (s, 1H), 8.79–8.84 (m, 6H),
8.20 (d, J = 7.5, 6H), 8.11 (d, J = 8.0, 2H), 7.99 (d, J = 8.0, 2H),
7.79–7.83 (m, 9H), 7.25–7.68 (m, 9H), 5.00–5.08 (m, 1H),
3.56–3.62 (m, 1H), 2.23–2.28 (m, 3H), 1.89–1.95 (m, 1H)),
1.33–1.47 (m, 4H), −2.80 (s, 1H); 13C NMR (125 MHz,
(CD3)2SO, 60 °C) δ 171.43, 171.04, 151.64, 148.19, 141.03,
141.01, 139.03, 137.38, 135.43, 134.26, 133.89, 132.19, 132.06,
130.87, 129.12, 128.58, 128.30, 128.05, 127.73, 127.65, 127.45,
127.33, 126.64, 126.48, 124.83, 121.35, 119.79, 119.66, 119.56,
117.87, 117.30, 54.58, 36.07, 33.76, 30.27, 24.38, 24.33.
HRMS [found (ESI+) 945.4067 [M + H]+, C65H48N6O2 requires
945.3912].
5-[4-(2-Aminoxy)-acetylamidophenyl]-10,15,20-triphenylporphyrin
(9)
A solution of 4 (20.0 mg, 0.02 mmol) in 50% TFA/DCM (2 mL)
was stirred at room temperature for 30 min, then it was treated
with activated Dowex-1 resin (hydroxide form) until the acid
was neutralised. The resin was filtered oﬀ, and the solvent was
evaporated. Filtration through a pad of silica gel (eluent: DCM)
followed by recrystallization (DCM/MeOH), gave 9 as a dark
purple solid (14 mg, 94%); mp 266–269 °C; UV-Vis (CHCl3),
nm (%): 418 (100), 515 (6.6), 548 (4.9), 590 (4.0), 646 (3.6);
1H-NMR (400 MHz, CDCl3) δ 8.86–8.77 (m, 8H), 8.41 (s, 1H),
8.20–8.12 (m, 8H), 7.95–7.89 (m, 2H), 7.76–7.68 (m, 9H),
5.85 (s, 2H), 4.40 (s, 2H) −2.79 (s, 2H); 13C-NMR (100 MHz,
CDCl3) δ 168.1, 165.4, 142.1, 138.4, 136.9, 135.1, 134.5, 131.1,
129.7, 127.7, 126.7, 120.2, 119.4, 118.1, 118.0, 75.3;
HRMS [found (ESI+) 703.2791 [M + H]+, C46H34N6O2 requires
703.2821].
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Preparation of porphyrin Zn complexes
5-[4-(4-Pentynoyl)-amidophenyl]-10,15,20-triphenyl porphyri-
nato zinc(II) (Zn-5). A solution of porphyrin 5 (42 mg,
0.056 mmol) in DCM (10 mL) was treated with Zn(OAc)2·2H2O
(63.0 mg, 0.288 mmol) in MeOH (1 mL) and the mixture was
stirred at 40 °C for 10 min then at room temperature until TLC
analysis showed complete conversion of the starting material.
The solution was then diluted with DCM (50 mL) and washed
with brine. The organic phase was dried (MgSO4), filtered, and
the solvent was evaporated to give (Zn-5) as a dark magenta
solid (45 mg, quant.); mp >300 °C; UV-Vis (CHCl3), nm (%):
420 (100), 548 (7.6), 587 (4.6); 1H-NMR (400 MHz, (CD3)2SO)
δ 10.56 (s, 1H), 8.93–8.80 (m, 8H), 8.27–8.12 (m, 10H),
7.87–7.83 (m, 9H), 2.97 (t, J = 2.4, 1H), 2.82–2.78 (m, 2H),
2.70–2.66 (m, 2H); 13C-NMR (100 MHz, (CD3)2SO) δ 170.0,
149.5, 149.3, 149.2, 142.8, 138.6, 137.5, 134.5, 134.2, 131.7,
131.5, 127.4, 126.6, 120.3, 120.2, 117.2, 83.8, 71.6, 35.5, 14.3.
5-[4-(11-Azido)-undecanoylamidophenyl]-10,15,20-triphenyl
porphyrinato zinc(II) (Zn-6). As for (Zn-5), but with 6 (18 mg,
0.02 mmol). Zn-6 was obtained as a dark purple solid (19 mg,
97%); mp 169–172 °C; UV-Vis (CHCl3), nm (%): 420 (100), 548
(7.8), 585 (4.7); 1H-NMR (500 MHz, (CD3)2SO) δ 10.32 (s, 1H),
8.88–8.80 (m, 8H), 8.26–8.05 (m, 8H), 7.85 (m, 9H), 7.62 (m,
2H), 1.76 (m, 2H), 1.59 (m, 2H), 1.45–1.35 (m, 16H); 13C-NMR
(125 MHz, (CD3)2SO) δ 176.5, 171.6, 149.5, 149.2, 149.2, 142.7,
138.8, 137.2, 134.5, 134.1, 132.0, 131.7, 131.5, 131.4, 128.8,
128.7, 127.4, 126.6, 120.2, 120.2, 117.1, 50.6, 36.6, 28.9, 28.9,
28.8, 26.0, 25.1, 22.4, 22.3.
5-[4-(11-Azido)-butanoylamidophenyl]-10,15,20-triphenyl-
porphyrin zinc(II) (Zn-7). As for (Zn-5), but with 7 (18.5 mg,
0.025 mmol). (Zn-7) was obtained as a dark purple solid
(15 mg, 71%); mp 181–183 °C; UV-Vis (CHCl3), nm (%): 420
(100), 547 (7.5), 584 (4.4); 1H NMR (400 MHz, (CD3)2SO)
δ 10.41 (s, 1H), 8.87–8.82 (m, 8H), 8.25–8.07 (m, 10H),
7.87–7.83 (m, 9H), 3.58 (t, J = 6.8, 2H), 2.65 (m, 4H), 2.05 (q, J =
7.0, 2H); 13C-NMR (125 MHz, (CD3)2SO) δ 170.7, 149.5, 149.3,
149.2, 142.8, 138.7, 137.3, 134.5, 134.2, 131.7, 131.6, 127.5,
126.6, 120.3, 120.2, 117.2, 50.4, 33.5, 24.4.
Peptide synthesis
All peptides were assembled according to the Fmoc strategy,
on Rink Amide MBHA Resin (Novabiochem, 200–400 mesh,
0.60 mmol g−1 loading) using an Activo P11 automated syn-
thesiser fitted with a reactor heating jacket. The synthesis was
performed on 250 mg of resin (0.15 mmol scale). Removal of
the Fmoc group from the resin was performed with 20% piper-
idine/DMF (2.5 mL, 4 × 3 min at 60 °C). The first residue
attachment for peptides starting with a Gly, Arg, or azidolysinyl
residue was performed manually at room temperature using
5 min preactivation then 1 h coupling with the amino acid
(4 eq.), DIC (4 eq.) and DIPEA (6 eq.). This was followed by
an acetylation step (Ac2O/DIPEA/DMF = 1/1/8, 2.5 mL,
1 × 10 min). For peptide 15 with C-terminal Cys, a low-racemi-
sation protocol by Angell et al. was employed,48 utilising a 1 h
coupling at room temperature without preactivation with
Fmoc-Cys(Trt)-OH (4 eq.), HATU (4 eq.), HOBt (4 eq.) and
collidine (4 eq.). Subsequent Fmoc deprotection steps were
performed using 25% piperidine/DMF (3 mL, 1 × 5 min,
1 × 10 min), with the chain elongation steps being performed
at 60 °C for 35 min using 3 eq. of each Fmoc-protected amino
acid (Fmoc-Arg(Pmc)-OH, Fmoc-Gln(Trt)-OH), Fmoc-Lys(Boc)-
OH, or Fmoc-Gly-OH), PyBOP (3 eq.), and DIPEA (6 eq.) in
DMF (4.3 mL) (35 min,). The Fmoc deprotection step was
omitted after the coupling of the final residue. The peptide
resin was washed thoroughly with DMF, DCM, MeOH and
Et2O, and dried in vacuo.
General procedure for the preparation of N-terminally ligatable
peptides (10)–(12), and (14) from resin-bound Tat(48–57)
peptide. These transformations were carried out manually,
using a disposable plastic reactor (Grace UK). 100 mg of
peptide resin (0.019 mmol, based on the initial loading) was
swollen in DCM, then the N-terminal Fmoc protection was
removed as described above. The resin-bound peptide was
then acylated as follows:
(10)–(12): derivatisation was carried with the appropriate
acid (3 eq.), HATU (2.9 eq.), and DIPEA (6 eq.) in DMF (2 mL)
for 1 h. Completion of the acylation was confirmed by the
Kaiser test.
(14): derivatisation was carried out using pyruvic acid
succinimido ester49 (2 eq.) and DIPEA (2 eq.) in DMF (2 mL)
overnight. Completion of the acylation was confirmed as
previously.
Following the acylation step, the resin beads were filtered
oﬀ under vacuum, and washed thoroughly with DMF, DCM,
MeOH, and Et2O, and dried in vacuo. For the cleavage and de-
protection of the ligatable peptides, the acylated peptidyl resin
was swollen in DCM for 20 min, then it was treated with TFA/
TIS/H2O (95/2.5/2.5) for 4 h. Cysteine-containing peptide (10)
was instead treated with TFA/TIS/H2O/EDT (95/2.5/2.5/1) for
3 h. The resin beads were filtered oﬀ, washed with TFA, and
the combined filtrates were evaporated to a small volume then
anhydrous Et2O was added. The resulting precipitate was
collected by centrifugation and was washed twice more with
Et2O. The precipitated material was dissolved in 1% aq. TFA,
filtered using a 0.2 μm syringe filter and the resulting solution
was directly purified by semi-preparative HPLC. The purified
peptides were then freeze-dried.
(10) (24 mg, 40%); HPLC: tR (Method 1): 4.07 min; HRMS
[found (ESI+) 749.9608 [M + 2H]2+, C58H117N33O12S2 requires
749.9635].
(11) (26 mg, 58%); HPLC: tR (Method 1): 3.76 min; HRMS
[found (ESI+) 738.4662 [M + 2H]2+, C60H116N32O12 requires
738.4720].
(12) (24 mg, 55%); HPLC: tR (Method 1): 6.53 min; HRMS
[found (ESI+) 803.0359 [M + 2H]2+, C66H131N35O12 requires
803.0353].
(14) (16 mg, 35%); HPLC: tR (Method 1): 3.91 min; HRMS
[found (ESI+) 489.3067 [M + 3H]3+, C58H115N32O13 requires
489.3102].
Preparation of ligatable peptide (13) via on-resin diazo
transfer. 100 mg of peptide resin was swollen in DCM and the
Organic & Biomolecular Chemistry Paper
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N-terminal Fmoc deprotection was removed as described
above. The resin was washed, and then swollen again in
mixture of DCM/MeOH/H2O (2/2/1) for 1 h. The resin was then
treated with imidazole-1-sulfonyl azide hydrochloride (121 mg,
0.7 mmol) DIPEA (273 μL, 1.40 mmol), and CuSO4·5H2O
(17 mg, 0.07 mmol) in DCM/MeOH/H2O (2/2/1, 2 mL). The
resin was shaken overnight, then the solution was discarded
and the beads were washed with deionised water, MeOH, and
DCM. Cleavage from the resin and isolation was carried out as
described above to give 12 (24 mg, 55%), tR (Method 1):
3.85 min; HRMS [found (ESI+) 474.6345 [M + 3H]3+,
C55H111N34O11 requires 474.6385].
Preparation of C-terminally ligatable peptides (15)–(18). For
peptides 16–18, the azidolysine-containing Tat, penetratin and
pVec sequences were assembled as described above on Rink
Amide MBHA resin (0.25 g, 0.60 mmol g−1 loading). For each
ligatable peptide, a sample of the peptide resin (50 mg) was
swollen in DCM, then the N-terminal Fmoc protection was
removed. Cleavage from the resin and side chain deprotection
were achieved by treatment with TFA/TIS/H2O (95/2.5/2.5/1)
(3 mL). All the solvents were evaporated under vacuum and the
residue was dissolved in TFA and cold Et2O was added. The
white solid precipitated was isolated by centrifugation. 16 and
18 were obtained directly in >90% purity as judged by HPLC
(see ESI†). For 17, the precipitate collected by centrifugation
was dissolved in 0.1% aq. TFA, filtered using a 0.2 μm syringe
filter and the resulting solution was directly purified by semi-
preparative HPLC. The purified peptide were then freeze-dried.
C-terminal Cys-containing peptide 15 was obtained in analo-
gous fashion to the N-terminal Cys-containing peptide 10 (see
above).
(15) (20 mg, 33%); HPLC: tR (Method 1): 3.90 min; com-
pound was previously described.9
(16) (54 mg, 67%). HPLC tR (Method 1) 7.61 min; [Found
(ESI+) 609.7098 [M + 3H]3+, C74H138N39O16 requires 609.7056].
(17) (33 mg, 65%). HPLC tR (Method 1) 5.06 min; [Found
(ES+) 557.8337 [M + 2H]2+, C48H85N21O8S requires 557.8330].
(18) (40 mg, 59%). HPLC tR (Method 1) 5.43 min; [Found
(ESI+) 745.8039 [M + 3H]3+, C98H179N40O20 requires 745.8076].
Ligation chemistry
N-terminal thiol-maleimide ligation-preparation of (19).
A solution of peptide Cys-Tat peptide 9 (9.1 mg, 3.6 µmol) and
maleoyl-porphyrin 3 (6.0 mg, 7.7 µmol) in DMSO (1.5 mL) was
treated with pyridine (73 µL) and stirred at room temperature
overnight, shielded from light. The mixture was diluted with
1.0% aq. TFA and directly purified by semi-preparative HPLC.
The purified conjugate was freeze-dried to give 19 as a dark
green solid (10.8 mg, 91%). HPLC: tR (Method 2): 7.12 min;
UV-Vis (0.1% aq. TFA), nm (%): 438 (100), 657 (14.6);
Fluorescence λmax. (0.1% aq. TFA, λexc. = 420 nm) 687 nm;
HRMS [found (ESI+) 760.7358 [M + 3H]3+, C109H154N39O15S
requires 760.7406].
C-terminal thiol-maleimide ligation-preparation of (20).
A solution of Tat-GYKC peptide 15 (39.1 mg, 13.1 µmol) and
maleoyl-porphyrin 3 (25.0 mg, 32.0 µmol) in DMSO (1.5 mL)
was treated with pyridine (150 µL) and stirred at room temp-
erature overnight, shielded from light. The mixture was diluted
with Et2O and TFA (350 µL) was added. A mixture of conju-
gated and unconjugated peptide was precipitated, which was
collected by centrifugation and dissolved in 1.0% aq. TFA
(10 mL). This solution was then directly purified by semi-
preparative. The purified conjugate was freeze-dried to give 20
as a dark green solid (37.0 mg, 75%). HPLC: tR (Method 2):
6.95 min; UV-Vis (0.1% aq. TFA), nm (%): 423 (100), 518 (13.5);
Fluorescence λmax. (0.1% aq. TFA, λexc. = 420 nm) nm (%): 651
(100), 714 (26); HRMS [found (ESI+) 876.4583 [M + 3H]3+,
C126H178N43O19S requires 876.4663].
Oxime ligation – preparation of (21). A solution of pyruvoyl-
Tat peptide 14 (3 mg, 1.3 µmol) and aminoxy-porphyrin 9
(4 mg, 5.7 µmol) in DMSO (500 µL) was treated with TFA
(5 µL), and the mixture was allowed to stand at room tempera-
ture overnight, shielded from light. The mixture was applied to
a solid phase extraction cartridge, which was washed with
0.1% aq. TFA, then 0.1% TFA in H2O/MeCN (80/20) and then
the desired conjugate was eluted with 0.1% TFA in H2O/MeCN
(50/50). The eluate obtained was evaporated to a small volume
and the desired conjugate was isolated by semi-preparative
HPLC and freeze-drying, to give 20 (3.3 mg, 75%). HPLC:
tR (Method 2): 6.91 min; UV-Vis (0.1% aq. TFA), nm (%):
439 (100), 658 (17.2); Fluorescence λmax. (0.1% aq. TFA, λexc. =
420 nm), 684 nm; HRMS [found (ESI+) 1076.0920 [M + 2H]2+,
C104H146N38O14 requires 1076.0948].
N-terminal CuAAC ligations – preparations of (22)–(25). (22):
a solution of azidoundecanoyl-Tat peptide (12) (2.0 mg,
0.79 µmol) in DMSO (400 µL), tBuOH (60 µL) and H2O (50 µL)
was treated with alkynyl-TPP (Zn-5) (2.0 mg, 2.6 µmol),
CuSO4·5H2O (12.4 µL of a 1 M solution in H2O, 12.4 µmol) and
sodium ascorbate (20 mg, 101 µmol). The mixture was allowed
to stand at room temperature, shielded from light for 1.5 h,
then it was diluted with 5.0% aq. TFA, left to stand at room
temperature for 30 min and directly purified by semi-prepara-
tive HPLC. The purified conjugate was freeze-dried, to give 22
as a dark green solid (1.2 mg, 45%). HPLC: tR (Method 2):
7.67 min; UV-Vis (0.1% aq. TFA), nm (%): 439 (100), 657 (17.2);
Fluorescence λmax. (0.1% aqueous TFA, λexc. = 420 nm) 689 nm;
HRMS [found (ESI+) 771.7775 [M + 3H]3+, C115H163N40O13
requires 771.7847].
(23): a solution of azidopeptide 13 (4.0 mg, 1.7 µmol) in
DMSO (500 µL) was treated with alkynyl-porphyrin (Zn-4)
(6.0 mg, 7.7 µmol), CuSO4·5H2O (1 mg, 8 µmol) and ascorbic
acid (2.5 mg, 14 µmol). The mixture was allowed to stand at
room temperature, shielded from light for 1.5 h, then it was
applied to a solid phase extraction cartridge. The cartridge was
washed with 0.1% aq. TFA, then 0.1% TFA in H2O/MeCN (80/
20), and then the desired conjugate was eluted with 0.1% TFA
in H2O/MeCN, (50/50). The eluate obtained was evaporated to
dryness, then the residue was dissolved in 20% aq. TFA and
the resulting solution allowed to stand at room temperature
until HPLC analysis indicated complete decomplexation of
the porphyrin moiety. The solution was then evaporated to
a small volume and the desired conjugate was isolated by
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semi-preparative HPLC and freeze-drying, to give 16 as a dark
green solid (4.1 mg, 79%). HPLC: tR (Method 2): 6.83 min; UV-
Vis (0.1% aq. TFA), nm (%): 438 (100), 657 (15.4); Fluorescence
λmax. (0.1% aq. TFA, λexc. = 420 nm) 685 nm; HRMS [found
(ESI+) 1066.5903 [M + 2H]2+. C104H145N39O12 requires
1066.5975].
(24): A solution of alkynyl-Tat peptide (11) (1.0 mg,
0.42 µmol) in DMSO (200 µL), tBuOH (30 µL) and H2O (30 µL)
was treated with azidoundecanoyl-porphyrin (Zn-6) (1.0 mg,
2.6 µmol), CuSO4·5H2O (6.2 µL of a 1 M solution in H2O,
6.2 µmol) and sodium ascorbate (10 mg, 50 µmol). The
mixture was allowed to stand at room temperature, shielded
from light for 3 h, then was diluted with 5.0% aq. TFA, left to
stand at room temperature for 30 min and directly purified by
semi-preparative HPLC. The purified conjugate was freeze-
dried, to give 24 as a dark green solid (3.1 mg, 77%). HPLC:
tR (Method 2): 7.61 min; UV-Vis (0.1% aq. TFA), nm (%):
437 (100), 651 (15.2); Fluorescence λmax. (0.1% aq. TFA, λexc. =
420 nm), 684 nm; HRMS [found (ESI+) 772.4495 [M + 3H]3+,
C115H167N40O132 requires 772.4549].
(25): A solution of alkynyl-Tat peptide 11 (6.0 mg, 8.1 µmol)
in DMSO (1.2 mL), tBuOH (180 µL) and H2O (180 µL) was
treated with azidobutanoyl-porphyrin (Zn-7) (6.0 mg,
2.6 µmol), CuSO4·5H2O (37.4 µL of a 1 M solution in H2O,
37.4 µmol) and sodium ascorbate (60 mg, 300 µmol). The
mixture was allowed to stand at room temperature, shielded
from light for 3 h, then was diluted with 5.0% aq. TFA, left to
stand at room temperature for 30 min and directly purified by
semi-preparative HPLC. The purified conjugate was freeze-
dried, to give 25 as a dark green solid (6.1 mg, 78%). HPLC:
tR (Method 2): 7.12 min; UV-Vis (0.1% aq. TFA), nm (%):
438 (100), 648 (15.9); Fluorescence λmax. (0.1% aq. TFA, λexc. =
420 nm), 684 nm; HRMS [found (ESI+) 554.8321 [M + 4H]4+,
C108H150N40O13 requires 554.8149].
N-terminal SPAAC ligation – preparation of (26). A solution
of azidoundecanoyl-Tat peptide 12 (7.8 mg, 4.9 µmol) and
DBCO-porphyrin 8 (8.6 mg, 9.1 µmol) in DMSO (4.0 mL) was
treated with pyridine (200 µL) and stirred at room temperature
overnight, shielded from light. The mixture was diluted with
1.0% aq. TFA and directly purified by semi-preparative HPLC.
The purified conjugate was freeze-dried to give 26 as a dark
green solid (9.8 mg, 65%). HPLC: tR (Method 2): 7.97 min; UV-
Vis (0.1% aq. TFA), nm (%): 438 (100), 661 (19), 606 (3);
Fluorescence λmax. (0.1% aq. TFA, λexc. = 420 nm), 691 nm;
HRMS [found (ESI+) 850.4899 [M + 3H]3+, C131H180N41O14
requires 850.4872].
C-terminal SPAAC ligations – preparation of (27–29). (27):
a solution of azidopeptide 16 (7.5 mg, 2.6 µmol) and
DBCO-porphyrin 8 (5.0 mg, 5.2 µmol) in DMSO (3 mL)
was stirred at room temperature overnight, shielded from
light. Purification by semi-preparative HPLC gave 27 as a dark
green solid (6.9 mg, 50%). HPLC: tR (Method 2): 7.44 min;
UV-Vis (0.1% aq. TFA), nm (%): 435 (100), 656 (29);
Fluorescence λmax. (0.1% aq. TFA, λexc. = 420 nm), 687 nm;
HRMS [found (ESI+) 924.5006 [M + 3H]3+, C139H186N45O18
requires 924.5002].
(28): As for 27, but with azidopeptide 17 (4.8 mg, 2.6 µmol)
and DBCO-porphyrin 8 (2.6 mg, 2.8 µmol). Purification by
semi-preparative HPLC gave 28 as a dark green solid (6.9 mg,
74%). HPLC: tR (Method 2): 7.90 min; UV-vis (0.1% aq. TFA),
nm (%): 433 (100), 652 (10); Fluorescence λmax. (0.1% aq. TFA,
λexc. = 420 nm), 684 nm; HRMS [found (ESI+) 697.6903
[M + 3H]3+, C115H132N30O8S requires 697.6850].
(29): As for 27, but with azidopeptide 18 (10.0 mg,
3.3 µmol) and DBCO-porphyrin 8 (3.1 mg, 3.3 µmol) in DMSO
(500 µL). Purification by semi-preparative HPLC gave 29 as a
dark green solid (9.0 mg, 69%). HPLC: tR (Method 1):
7.61 min; UV-Vis (MeOH), nm (%): 415 (100), 513 (12.96), 547
(9.50), 590 (8.23), 646 (7.81); Fluorescence λmax. (MeOH, λexc. =
420 nm) nm (%) 653 (100), 715 (34); HRMS [found (ESI+)
795.4614 [M + 4H]4+, C163H228N46O22 requires 795.4529].
Cell lines and cultivation
MC28 cells, a methylcholanthrene-induced fibrosarcoma
cell line, were grown in DMEM supplemented with 10%
FCS. Human breast cancer cells (MCF-7) were grown in
DMEM-F12 medium containing 10% FCS. Cells were incu-
bated at 37 °C in a humidified atmosphere containing 5%
CO2. Unless otherwise stated materials for the cell studies were
purchased from Sigma-Aldrich Gillingham, UK.
Cellular uptake and confocal microscopy. MC28 cells were
seeded in small Petri dishes with a glass cover slip bottom
(Fluorodish, World Precision Inst. UK) and allowed to attach
overnight. Cells were then incubated for 24 h with conjugate
20 (2.5 µM). Afterwards, culture medium was removed and
replaced with fresh medium containing LysoTracker Green
(100 nM) 30 min before microscope imaging. Cells were then
washed 2 times with PBS and incubated with drug-free/phenol
red-free medium for the confocal imaging using an Olympus
laser scanning confocal microscope (FluoView FV1000, 60×
magnification, NA 1.20, Olympus UK Ltd, Essex, UK).
Fluorescence from the photosensitiser was recorded within the
range of 620–720 nm using a 405 nm laser for the excitation.
For the LysoTracker Green imaging, cells were illuminated at
488 nm and the fluorescence signal was recorded at
500–550 nm. Colocalisation analysis and image processing
were performed with ImageJ software.
In vitro PDT phototoxicity study. MC28 and MCF-7 cells
were seeded out at a density of 5000 cells in 96 well plates. The
cells were allowed to attach to the bottom of the wells for 24 h.
The next day, cells were incubated with various concentrations
of photosensitiser for 18 h. The cells were then washed twice
with PBS and incubated with drug-free culture medium for
4 h. Afterwards, the cells were exposed to increasing doses of
light using a blue LumiSource® flatbed lamp with peak emis-
sion at 420 nm and 7 mW cm−2 output (PCI Biotech, Oslo,
Norway). Cell viability was evaluated 48 h after light illumina-
tion using a standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. Each experiment was
carried out in triplicate.
In vitro PDT/PCI phototoxicity study. MC28 cells were
seeded out at a density of 3000 cells in 96 well plates overnight.
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Cells were then treated with 19 or 26 (50 nM) or saporin
(Sigma-Aldrich Gillingham, UK) (20 nM) for 18 h separately.
Another group of cells were co-incubated with saporin (20 nM)
and 19 or 26. Cells were then washed twice with PBS and incu-
bated for a further 4 h with fresh full medium. Irradiation was
carried out for up to 5 min using a blue LumiSource® flatbed
lamp with peak emission at 420 nm and 7 mW cm−2 output
(PCI Biotech, Oslo, Norway). Cell viability was determined by
means of the MTT assay 72 h after the light exposure. Each
experiment was carried out in triplicate.
Statistical analysis
Data were analysed using two-tailed Students T-test with appro-
priate testing post hoc using Prism 6 software. The dose
required to reduce viability by 50% (LD50) was also calculated
using Graphpad Prism. Error bars from the mean show ±stan-
dard deviation (SD). Values of P < 0.05 were considered to be
significant.
Conclusions
Bioconjugation strategies oﬀer a highly eﬃcient and flexible
means to generate conjugates between hydrophobic porphyr-
ins and polyfunctional CPPs under very mild conditions.
These amphiphilic photosensitisers with regiospecific attach-
ment of a tetrapyrrole component within the peptide backbone
are eﬀective agents for both targeted PDT and PCI. As exempli-
fied in this study, strain-promoted azide–alkyne ligations oﬀer
an ideal way to repurpose simple porphyrin derivatives for PCI
by attachment to a variety of CPPs. This approach opens the
way for adapting clinically relevant photosensitisers with the
most attractive spectroscopic properties that are currently used
in PDT for minimally invasive therapies in conjunction with
selected targeted CPPs.
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